Cardiovascular disorders are the leading cause of mortality worldwide. Berberis vulgaris (B. vulgaris) is a commonly used plant in traditional medicine. In recent studies, B. vulgaris showed antiarrhythmic, antihypertensive, anticholinergic, and cardioprotective effects. We reviewed the literature to explore the possible prophylactic and therapeutic roles of B. vulgaris in cardiovascular medicine. A computer literature search was conducted to identify all relevant studies that have investigated the role of B. vulgaris in prevention or treatment of cardiovascular diseases. We also searched the citations of the retrieved articles. Using a systematic approach, we conducted a scoping review that included a total of 37 articles. Twelve studies examined the antihypertensive effects of B. vulgaris, seven studies investigated its antiarrhythmic effects, while its inotropic and cardioprotective effects were evaluated in four and eight studies, respectively. B. vulgaris showed a beneficial effect in reducing blood pressure, enhancing cardiac contractility, and protection from reperfusion injury. However, the mechanisms of these effects are still under investigation. Moreover, it could modify major risk factors for cardiovascular disorders, such as oxidative stress, hyperglycemia, and hyperlipidemia. Further studies are needed to translate these findings into effective cardiovascular medications.
Introduction
Cardiovascular disorders are the leading cause of morbidity and mortality worldwide (1) . According to the American heart association (AHA), about 16.5% of the global mortality can be attributed to hypertension, of which 45% are caused by coronary heart disease (2) . Most of these disorders are untreatable and the current pharmacological strategies only aim at disease control (3) . Adding to this, various biochemical compounds, especially those used in the treatment of arrhythmia and heart failure, have serious adverse events. Therefore, there is a growing trend towards using medicinal plants in health care generally and cardiovascular medicine, in particular (4) .
Berberis vulgaris (B. vulgaris) is a shrub of the plant family Berberidaceae that grows in northwest Africa, western Asia, central, and southern Europe. Its fruit is an oblong red berry that ripens in late summer and autumn. It has obovate leaves and pendulous yellow flowers (5) . It contains multiple phenolic compounds, organic acids, flavonoids (anthocyanins), protoberberines, and alkaloids, to which its biological activities are attributed ( Figure  1 ) (4) .
For 3000 years in traditional medicine, B. vulgaris has been used to stop chronic bleeding, relieve arthralgia, fight infections, and treat urinary stones due to its diuretic effect (6) . Therapeutic uses of B. vulgaris have been a focus for experimental research recently. Both animal and human trials have concluded that its extracts may have antioxidant (7, 8) , antiinflammatory (9) , anti-mutagenic, antimicrobial, and anti-parasitic activities (10) . It has also been tested for the management of chronic cholecystitis, non-alcoholic fatty liver disease (11) , osteoarthritis, and other rheumatoid disorders (12) . Its fruit is safe for human intake and has been approved by the FDA (13) .
In cardiovascular medicine, B. vulgaris and its active constituents showed antiarrhythmic, antihypertensive, anticholinergic, anti-inflammatory, and cardioprotective effects from ischemia/reperfusion (I/R) injury (14, 15) . Despite its numerous applications, the mechanism of action for most of its effects is not yet clear (4) . This review explores the potential role of B. vulgaris in prevention or treatment of cardiovascular disorders.
Materials and Methods

Data sources
We performed a computer literature search of the following authentic databases: PubMed, Persian Electronic Scientific Information Database (SID), Iran medex, and Natural Medicines Comprehensive Database for all preclinical and human studies of b. vulgaris in cardiovascular medicine, using the search terms "Barbery", "Berberis vulgaris", "Berberine", "Berbamine", "Cardiovascular", "Heart", and "Hypertension". We also searched the reference list of retrieved records for any relevant studies.
Study selection
We included original studies of all designs, including preclinical (in vivo and in vitro) and human studies provided that they evaluated the prophylactic or therapeutic roles of B. vulgaris or its active constituents in cardiovascular medicine. We excluded secondary reports (literature reviews, systematic reviews, or meta-analyses) and non-English articles. Two authors independently reviewed the titles and abstracts of the search results and if the abstract was not conclusive, the full text was obtained to make a cut-off decision.
Data extraction
For each included study, two independent authors extracted the following data: first author's name, year of publication, used active constituent, animal/cellular model, findings, and possible mechanisms.
Results
Our search strategy retrieved 721 records. After abstract and full-text screening, we included 33 full-text articles. An additional four articles were retrieved by screening the reference list of included articles. Details of our literature search and screening process are illustrated in Figure 2 .
Antihypertensive effects
Several in vitro and animal studies have shown an antihypertensive effect for B. vulgaris. However, the mechanisms and vascular sites for this effect are still debatable. Fatehi et al reported that the immediate reduction of blood pressure after B. vulgaris intake can be attributed to modulation of both cardiac and vascular contractility (16, 17) . In vitro studies have shown that pretreatment of isolated aortic rings and mesenteric vascular beds with B. vulgaris extract decreases their contractile response to phenylephrine administration. This effect may be attributed to alpha-adrenoreceptor antagonism (18) . Moreover, the augmentation of K + currents through activation of 4-aminopyridine-sensitive K + channels and the inhibition of intracellular Ca +2 release from caffeinesensitive pools can initiate relaxation of vascular smooth muscles and vasodilatation (19) (20) (21) (22) . Animal studies have also suggested a central nervous mechanism for B. vulgaris antihypertensive effect, based on the observation of parallel reduction of blood pressure and heart rate (17) . Other mechanisms have been suggested as inhibition of angiotensin-converting enzyme and direct release of NO/cGMP from rat aortic rings (19) and the potentiation of acetylcholine (23) . Berberine-induced vasodilatation of rat and rabbit aorta, most probably through α1-adrenoceptor antagonism. It also inhibited the contractile response of the aorta to norepinephrine and phenylephrine exposure
Bova et al 1992 (28) Berberine Guinea pig (in vitro)
Berberine inhibited the aortic contractile response to norepinephrine and histamine, but this effect is unlikely to be mediated through voltage-gated calcium channels
Chiou et al 1991 (29) Berberine
Rats (in vitro)
Berberine-induced vasodilatation of the rat mesenteric artery [Directly by inhibiting Ca +2 release from internal stores and indirectly by releasing endothelial derived relaxing factor (EDRF)]
Chun et al 1979 (23) Berberine Rats (in vivo) Berberine intravenous infusion lowered the blood pressure and the heart rate of rats, most probably through inhibition of true cholinesterase and potentiation of acetylcholine levels
Although its effects were widely studied in systemic hypertension, few studies have investigated the possible therapeutic effect of B. vulgaris extract in pulmonary hypertension. Mahdavi et al showed that B. vulgaris extract can be as effective as sildenafil in reducing right ventricular systolic pressure and right ventricular hypertrophy in monocrotaline-induced pulmonary hypertension (24) .
Antiarrhythmic effects
Several animal studies have shown that the active compounds from B. vulgaris extracts can have antiarrhythmic properties, such as prolonging the action potential duration (APD), increasing the atrial refractory period, and suppression of delayed afterdepolarization (30, 31) . Berberine has been suggested to act as a class IA or III antiarrhythmic agent. In vitro studies reported different possible mechanisms for the observed effects of berberine, such as K + channels blockade (32, 33) , decreasing Na + influx (30) , and increase of [Ca +2 ]i (34) . Berberine can indirectly supplement anti-arrhythmic drugs by its inhibitory effect on the human CYP3A4 enzyme, through which many of these drugs are metabolized, increasing their potency. However, this interaction may require adjusting the anti-arrhythmic dosage and should be prescribed by a specialist (35) .
In a clinical study by Zeng and Li, in patients with congestive heart failure (CHF), berberine reduced the frequency of ventricular premature complexes and increased the left ventricular ejection fraction (EF) (36) . Other pharmacological studies have shown that it can prevent the development of ventricular fibrillation (VF) due to its inhibitory effect on K + channels (32, 33) . Although berberine has not been tested in large-scale clinical studies, the existing body of literature shows a great potential for this compound as a future anti-arrhythmic drug. Berberine increased the APD in a concentration-dependent manner in isolated guinea pig ventricular myocytes. Berberine prolonged the repolarization phase of AP by inhibiting the delayed rectifier K + currents and increasing the L-type Ca +2 currents (ICa)
Rats (in vitro)
Berberine possesses an antiarrhythmic activity via suppression of delayed afterdepolarizations (suppressed amplitude at 3 μm and suppressed frequency at 1 mg/kg), which is likely due to the reduction of Na + influx Shaffer 1985 (38) Berberine
In spontaneously beating right atria, berberine (1 x 10 5 -3 x 10 4 M) caused bradycardia, which was not prevented by atropine. It also had a positive inotropic effect by enhancing both the force-velocity relationship and the duration of the active state. The mechanisms for these actions may include an alteration in the trans-sarcolemmal flux of calcium and inhibition of intracellular calcium sequestration system
Cardioprotective effects
Ischemic preconditioning (IPC) is a powerful adaptive response to protect the heart from subsequent ischemic damage (39) . Ischemia/Reperfusion injury is thought to be mediated through intracellular Ca +2 overload due to the reduced activity of sarcoplasmic reticulum Ca +2 ATPase, leading to contractile dysfunction and activation of lytic proteases, such as calpain, which digests cytoskeleton and myofilament proteins including troponin I and T (40, 41) .
Several studies have discussed the cardioprotective effects of berbamine; however, its mechanism is still under investigation (4). It is suggested that berbamine inhibits calpain by maintaining Ca +2 homeostasis.
Another suggested mechanism is the activation of phosphoinositide-3 kinase and protein kinase B enzymes, leading to inhibition of the glycogen synthetase kinase-3β (GSK 3β) and opening the mitochondrial ATP-sensitive K channels (mitoKATP) (42). Zhang et al noticed that low concentrations (10-100 nmol/l) of berbamine improve post-ischemic cardiac function in a concentration-dependent manner. However, that effect diminished with higher concentrations of 300 nmol/l in Langendroff-perfused rat hearts and 100 nmol/l in isolated cardiac cells (32) .
Other studies have shown that berberine can also prevent cardiac hypertrophy in rats that were exposed to high doses of L-thyroxine or underwent surgical binding of the aorta. Possible mechanisms are elevating cardiac NO content, Na + /K + ATPase and Ca +2 ATPase activities, as well as decreasing plasma levels of norepinephrine and controlling the sympathetic tone (43, 44) . 
Rats (in vivo)
In rats with cardiac hypertrophy, berberine decreased the plasma levels of norepinephrine, controlled the total sympathetic tone, and inhibited the progress of cardiac hypertrophy Zeng et al 2003 (46) Berberine
Berberine alleviated ischemia/reperfusion (I/R) injury and attenuated apoptosis in rat neonatal myocytes that were exposed to I/R. Berberine pretreatment of myocytes reduced lactate dehydrogenase (LDH) release and methylenedioxyamphetamine (MDA) formation in I/R groups, and inhibited apoptosis in ischemia and reperfusion groups Zhou et al 2001 (47) Berberine
Rats (in vitro)
Berberine pretreatment significantly reduced the degree of verapamil-induced heart failure in the experimental group, compared to the control group. Zhang et al 1992 (32) Berbamine
Berbamine alleviated myocardial I/R injury through preservation of Na + -K + ATPase activity, attenuation of ischemia-induced Na + overload and reperfusion-induced Ca +2 overload. Also, it reduced free radicals generation during reperfusion. 
Berbamine compound E6 inhibited calmodulin-dependent myosin light chain kinase (MLCK) in a dose-dependent manner, an effect which was antagonized by the addition of more calmodulin. This suggests that berbamine has an inotropic effect by competitive antagonism with calmodulin Xu 1986 (51) O-(4-ethoxyl-butyl) berbamine (EBB)
Human trial EBB had a more potent calmodulin antagonist activity than berbamine. This antagonism is competitive because it can be reversed by adding higher doses of calmodulin
Inotropic effects
Berberine is used in the East to treat CHF (46) . Several studies have investigated the underlying mechanisms of the positive inotropic effect (PIE) of B. vulgaris extracts. Zhang et al showed that the PIE of berbamine can be attributed to increasing myofilament Ca +2 sensitivity, thus avoiding the adverse events of several cardiotonic agents that improve cardiac contractility through increasing intracellular Ca +2 concentration (50) . Improving myofilament Ca +2 responsiveness can be explained by increasing cytosolic protein kinase C (an enzyme family that regulates cardiac contraction through controlling Ca +2 transients and myofilament Ca +2 sensitivity).
They also revealed that high concentrations of berbamine (300 nM) can be associated with a negative inotropic effect (NIE) through suppression of Ca +2 transients and cellular shortening, thus suggesting a biphasic concentration-dependent regulation of cardiac function (50) . In another study by Li et al (48) , high concentrations of berbamine resulted in inhibition of cardiac muscle contraction in the isolated rabbit hearts. Moreover, berbamine and its active derivatives were proven to inhibit calmodulin at micromole concentrations (51, 52) .
Antiplatelet effect
Few studies have reported a possible antiplatelet effect of B. vulgaris extracts and berberine, in particular. In a clinical study by Huang et al, using berberine increased thrombolysis, induced by plasminogen activators (53). Feng et al reported that berberine could be more efficacious than aspirin in preventing platelet aggregation in patients with atherosclerotic cerebral infarction (54) . In another study by Fukuda et al, berberine could directly inhibit different stages of platelet-dependent inflammatory processes in a dosedependent manner (55) .
Several mechanisms have been proposed for the observed antiplatelet effect of berberine, such as inhibition of arachidonic acid metabolism, reduction of thromboxane A2 release from platelets (56) , delineation of the calcium influx (57) and the partial agonist effect on platelet α2-adrenoceptors (53, 58) . However, the exact mechanism has not been fully uncovered. Further studies are warranted to understand the molecular mechanism behind this effect before translation into large randomized clinical trials.
Discussion
Our study adds to the literature by outlining the effects and mechanisms of B. vulgaris in cardiovascular medicine, making it a strong candidate for further clinical trials and human applications. The current literature suggests that B. vulgaris extracts can directly influence the cardiovascular system through their cardioprotective, inotropic, and antihypertensive effects. However, some of the mechanisms, underlying these effects, are still largely unknown and have not been tested in clinical trials due to lack of preclinical evidence. Figure 3 summarizes the mechanisms of B. vulgaris cardiovascular actions. Moreover, B. vulgaris extracts can protect against cardiovascular pathologies indirectly through targeting the associated risk factors. They exert a potent antioxidant activity through decreasing the formation of cellular thiobarbituric acid reactive species formation (TBARS) and nitric oxide (NO), as well as increasing the activity of glutathione peroxidase (GPx) and superoxide dismutase (SOD) (7, 8) . There is a wealth of evidence regarding the hypoglycemic and hypolipemic properties of berberine. The hypoglycemic effect of berberine can be attributed to improving insulin sensitivity, inhibiting glucogenic enzymes, delaying carbohydrate absorption, and increasing cellular glucose uptake (59) (60) (61) , while the hypolipemic effects are related to inhibiting adipogenesis and increasing LDL-C uptake by increasing its cellular receptors (62, 63) . These effects can act in synergism with the direct cardiovascular effects of B. vulgaris.
The proven effects of berberine can have numerous applications, such as controlling stenosis after balloon angioplasty (25) , replacing or supplementing antihypertensive and antiarrhythmic drugs, being an ideal drug for CHF due to its vasodilator, inotropic, and lusitropic effects (64) . However, lack of evidence from randomized clinical trials limits the acceptability of the results from small clinical studies and further use in clinical practice (65) .
Dosage: The therapeutic dose of B. vulgaris, used in most clinical situations, is about 200 mg for three to four times daily. Its extracts are standardized to contain 8% to 12% isoquinoline alkaloids (4). B. vulgaris extracts are widely available in the form of capsules, solutions, and topical preparations, such as ointments and tinctures. It can be used as a supplement for food and tea (66) .
Safety: No toxic effects have been reported at doses used for clinical purposes. However, overdosage has been linked to vertigo, convulsion, nasal bleeding, kidney failure, skin and eye inflammation, and hypoglycemia (67). According to an animal study by Peychev, B. vulgaris is moderately toxic (LD50= 2.6± 0.22 g/kg body weight in mice). It is not recommended to exceed a daily dose of 500 mg (68) .
According to a study by Arayne et al, B. vulgaris should not be used during pregnancy because it can cause uterine constriction, leading to miscarriage. Furthermore, large doses of berberine are warranted to have a teratogenic effect (69) . B. vulgaris fruits contain dihydro-palimitinum hydroxide, which exerts anti-estrogen activities, causing endometrial atrophy and fetal malnourishment. Moreover, it should be avoided in jaundiced infants because it has bilirubin displacement properties (70) . Despite the lack of clinical evidence, it is not recommended for use in infants below 2 years of age and elders over 65 years, as well as breastfeeding women (4) . Individuals who suffer any organ dysfunction should only use it after medical consultation.
Recommendations: The mechanism of action and the bioactive components of these extracts need further exploration. Moreover, further information regarding dosage, duration, and pharmacokinetics are needed to optimize its pharmacological use. Larger clinical trials with longer follow-up periods are necessary to detect rare adverse events and investigate the long-term safety of B. vulgaris extracts. Randomized data about cost-effectiveness and quality of life, in comparison to the standard drugs of cardiovascular disorders, would be beneficial. Integrated use of B. vulgaris extracts with the current cardiovascular drugs should be considered and the possible interaction between these agents should be characterized. It is also essential to increase awareness of alternative medicine strategies among health care professionals to enable them to provide alternative treatments for their patients who are not responding or intolerant to current medications (71) .
Conclusion
B. vulgaris showed a beneficial effect in reducing blood pressure, enhancing cardiac contractility, and protection from reperfusion injury. However, the mechanisms of these effects are still under investigation. Moreover, it can modify major risk factors for cardiovascular disorders, such as oxidative stress, hyperglycemia, and hyperlipidemia. Further trials are needed to translate these findings into effective cardiovascular medications.
